ArticleScientific reports2025
Deduction of full factorial design of HPLC technique for the simultaneous analysis of meloxicam and esomeprazole in their laboratory prepared tablets.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sustainable high-performance injection geopolymers, role of GGBFS and water-to-binder ratio in strength, microstructure, and predictive modeling.Scientific reports · 2025Article
- FDA validated ecofriendly HPTLC method for quantification of Florfenicol and Meloxicam in bovine tissues with sustainability assessment.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A reversed phase HPLC method with UV detection was designed for the first time for the simultaneous estimation of meloxicam and esomeprazole in their combined tablet dosage forms. Full factorial design was used for rapid optimization of the proposed method. Chromatographic separation was reached using isocratic elution on C18 column. The mobile phase was a mixture of methanol: acetonitrile: 0.05 M potassium dihydrogen phosphate buffer at pH 5, adjusted using phosphoric acid and/or NaOH when needed. The flow rate was 1 mL/min and the injection volume was 20 µL. The detection wavelength was 230 nm. The working ranges of the method were 5.0-100.0 and 10.0-100.0 µg/mL, LOD values were 0.8 and 1.8 µg/mL and LOQ values were 2.6 and 5.5 µg/mL for meloxicam and esomeprazole, respectively. The proposed method was successfully applied to their combined tablet dosage forms with acceptable % recoveries (100.4 - 100.7%) obtained. Four methods were used to evaluate the greenness of the proposed method, suggesting the acceptability of the greenness of the proposed method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.